Title |
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study
|
---|---|
Published in |
PLOS ONE, March 2013
|
DOI | 10.1371/journal.pone.0058438 |
Pubmed ID | |
Authors |
Christian Wolf, Jagdev Sidhu, Christian Otoul, Dexter L. Morris, Jennifer Cnops, Jorg Taubel, Barbara Bennett |
Abstract |
Lymphocyte inhibition by antagonism of α4 integrins is a validated therapeutic approach for relapsing multiple sclerosis (RMS). |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 3% |
Germany | 1 | 3% |
Unknown | 38 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 18% |
Student > Master | 5 | 13% |
Researcher | 5 | 13% |
Other | 4 | 10% |
Student > Bachelor | 2 | 5% |
Other | 3 | 8% |
Unknown | 14 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 25% |
Agricultural and Biological Sciences | 4 | 10% |
Nursing and Health Professions | 3 | 8% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Neuroscience | 2 | 5% |
Other | 3 | 8% |
Unknown | 16 | 40% |